As an important signal in the receptor tyrosine kinase (RTK) pathway, EGFR or variant III (EGFRvIII) is overexpressed in over 40% of GBM patients [45] and is an attractive target for the development of targeted therapies, such as geftinib, neratinib, and CAR-T cells [5]. This evidence concerns the gene EGFR and glioblastoma.